CN113633664A - Capsule for treating atrial and ventricular premature beat and its preparing process - Google Patents
Capsule for treating atrial and ventricular premature beat and its preparing process Download PDFInfo
- Publication number
- CN113633664A CN113633664A CN202111106550.8A CN202111106550A CN113633664A CN 113633664 A CN113633664 A CN 113633664A CN 202111106550 A CN202111106550 A CN 202111106550A CN 113633664 A CN113633664 A CN 113633664A
- Authority
- CN
- China
- Prior art keywords
- glucan
- capsule
- beta
- tuna oil
- coenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 38
- 208000000418 Premature Cardiac Complexes Diseases 0.000 title claims abstract description 19
- 230000002861 ventricular Effects 0.000 title claims abstract description 11
- 230000001746 atrial effect Effects 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title description 3
- 230000008569 process Effects 0.000 title description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 29
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 29
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 26
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 26
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 24
- 210000002837 heart atrium Anatomy 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 210000000170 cell membrane Anatomy 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 8
- 229940041514 candida albicans extract Drugs 0.000 claims description 8
- 239000012138 yeast extract Substances 0.000 claims description 8
- 102100032487 Beta-mannosidase Human genes 0.000 claims description 7
- 108010055059 beta-Mannosidase Proteins 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 108090000145 Bacillolysin Proteins 0.000 claims description 5
- 102000035092 Neutral proteases Human genes 0.000 claims description 5
- 108091005507 Neutral proteases Proteins 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 206010015856 Extrasystoles Diseases 0.000 claims description 4
- 229920001503 Glucan Polymers 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 230000001804 emulsifying effect Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000007751 thermal spraying Methods 0.000 description 3
- 244000144730 Amygdalus persica Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000014290 Artemisia anomala Nutrition 0.000 description 1
- 241000123844 Artemisia anomala Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 240000008519 Prunus americana Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016788 immune system process Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- -1 polyene quinone compound Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a capsule for treating atrial and ventricular premature beat, which comprises a capsule and medicinal components arranged in the capsule, wherein the medicinal components comprise the following components: coenzyme Q10, tuna oil and beta-glucan, wherein the mass ratio of the coenzyme Q10 to the tuna oil is 1: 18 to 1: 22, the mass ratio of the tuna oil to the beta-glucan is 1: 0.8 to 1: 1.2. the invention also provides a manufacturing method of the capsule for treating the premature beat of the atria and the ventricles. The invention has the advantages of simple components and good treatment effect, and the preparation method is simple and convenient for industrialization.
Description
Technical Field
The invention relates to a capsule for treating premature beat of atria and ventricles and a preparation method thereof, belonging to the field of medicaments.
Background
Premature beat is also called extrasystole, which is called "premature beat" for short, and refers to the heart beat caused by the premature beat triggered by ectopic pacing point. Premature beats are the most common and common ectopic rhythms. According to the difference of the origin of ectopic beat, the premature beat can be divided into three types, namely atrial, atrioventricular junctional and ventricular. With ventricular nature being the most common, premature beats may be sporadic or sporadic, or may occur frequently. In the prior literature, there are medicines for treating premature heart beat disclosed, for example, in the chinese patent application entitled "chinese traditional medicine preparation for treating premature heart beat" with publication No. CN101579509B, a chinese traditional medicine preparation for treating premature heart beat is disclosed, the weight ratio of the raw materials for preparing the effective components is: 30-60 parts of radix cynanchi wilfordii, 20-40 parts of codonopsis pilosula, 15-30 parts of prepared rehmannia root, 10-30 parts of salvia miltiorrhiza, 10-30 parts of fructus trichosanthis, 15-30 parts of kudzuvine root, 15-30 parts of herba lycopi, 10-20 parts of radix curcumae, 10-20 parts of radix sophorae flavescentis, 10-30 parts of artemisia anomala, 5-10 parts of peach kernel and 10-20 parts of safflower. The existing medicine has complex components and relatively higher risk of generating side effects, and simultaneously increases the difficulty of manufacturing.
Accordingly, the present inventors have made extensive studies to solve the above problems and have made the present invention.
Disclosure of Invention
The invention aims to provide a capsule for treating atrial and ventricular premature beat, which has simple components and good treatment effect, and the invention also aims to provide a manufacturing method of the capsule.
In order to achieve the purpose, the invention adopts the following technical scheme:
a capsule for treating atrial and ventricular premature beat comprises a capsule and medicinal components arranged in the capsule, wherein the medicinal components consist of the following components: coenzyme Q10, tuna oil and beta-glucan, wherein the mass ratio of the coenzyme Q10 to the tuna oil is 1: 18 to 1: 22, the mass ratio of the tuna oil to the beta-glucan is 1: 0.8 to 1: 1.2.
in a preferred embodiment of the present invention, the mass ratio of coenzyme Q10 to tuna oil is 1: 20, the mass ratio of the tuna oil to the beta-glucan is 1:1.
the invention also provides a preparation method of the capsule for treating atrial and ventricular premature beat, which is characterized in that coenzyme Q10 is dissolved in tuna oil to form mixed liquid, and the mass ratio of the coenzyme Q10 to the tuna oil is 1: 18 to 1: 22, crushing the beta-glucan into particles of 0.5 to 1.5 microns by using a jet mill, uniformly distributing the beta-glucan in the mixed solution by using an emulsification homogenizer, and then preparing into capsules, wherein the mass ratio of the tuna oil to the beta-glucan is 1: 0.8 to 1: 1.2.
in a preferred embodiment of the present invention, the β -glucan is produced by: washing saccharomyces cerevisiae with deionized water to prepare a bacterial suspension, and filtering to remove impurities; performing enzymolysis treatment with mannanase and yeast extraction enzyme to obtain partially degraded cell membrane and yeast extract, and centrifuging to obtain cell membrane precipitate; preparing the cell membrane precipitate into suspension by adopting phosphate buffer solution, and performing enzymolysis treatment by using a complex enzyme consisting of mannanase, yeast extract enzyme and neutral protease; after enzymolysis, centrifugally washing the mixture by using deionized water until supernatant is clear and transparent, and centrifugally precipitating the supernatant to obtain wet beta 1,3-1,6 glucan; drying to obtain beta-glucan powder.
In the invention, the coenzyme Q10 is the only coenzyme Q substance naturally existing in cells in human bodies, also called ubiquinone, and is a fat-soluble polyene quinone compound; mainly exists on the inner membrane of the mitochondria of the cells of the heart, the liver and the kidney and is an important hydrogen donor in the respiratory chain of biological cells. Coenzyme Q10 is a natural antioxidant and activator of cellular metabolism synthesized by the cell itself. Coenzyme Q10 also directly affects the immune system and aging process of the body, and if coenzyme Q10 is deficient in the human body, the body has many health problems, such as arrhythmia, heart failure, arteriosclerosis, heart attack, hypertension or muscle atrophy and other symptoms. Coenzyme Q10 is present in the heart in the highest amounts and, as an important cofactor, plays a key role in the formation of ATP in the oxidative phosphorylation of mitochondria. It helps the biological energy conversion in vivo, and energy ATP is generated through an electron transfer chain in the tricarboxylic acid cycle, so that the myocardial cells continuously and repeatedly obtain ATP, and the heart can continuously keep beating.
In the present invention, the basic components of tuna oil are the Omega-3 series unsaturated fats EPA and DHA. EPA has effects of reducing blood viscosity, decomposing excessive fat in blood vessel wall, reducing triglyceride and cholesterol (LDL) concentration, cleaning thrombi, reducing blood lipid, and preventing and improving cardiovascular disease and cerebrovascular disease; DHA is the material basis for the generation of brain cells, and the lack of DHA causes brain development disorder, hypomnesis and senile dementia.
In the invention, the coenzyme Q10 provides sufficient energy and oxygen for the heart, protects the cardiovascular system and strengthens the heart function; tuna oil can reduce blood viscosity, dissolve redundant fat in blood vessel wall, reduce triglyceride and cholesterol (LDL) concentration, and achieve the effects of clearing thrombus, reducing blood lipid, and softening blood vessel; the beta-glucan can activate lymphocytes, generate antibodies to improve the immunity of the organism, remove free radicals and assist damaged tissues to accelerate the recovery of the generated cytokines.
Preferably, the beta-glucan of the invention adopts a unique mild purification process, has high product purity (the content is at least more than 95 percent), and maintains the natural three-dimensional structure and a pure anaerobic growth environment of the yeast, which are very important for the activity (similar to the three-dimensional structure in natural yeast cells). The beta-glucan can activate lymphocytes to generate antibodies, the antibodies and antigens are combined, then complement is combined, the complement activates and kills pathogens, and the beta-glucan can also activate stem cells and macrophages to secrete various cytokines (interleukins), promote proliferation and differentiation of target cells, and participate in regulating immune response of an organism and inhibiting inflammatory response.
Detailed Description
In order to further explain the technical solution of the present invention, the following detailed description is made with reference to the embodiments. Example 1:
the oil melting pot is operated in an oxygen-free state in advance, namely, the oil melting pot is vacuumized, the vacuum degree reaches more than minus 0.9Mpa, a vacuum valve is closed, and nitrogen is supplemented to the normal pressure. Repeating the operation for three times, opening the feed inlet, slightly opening nitrogen, adding coenzyme Q102 kg and tuna oil 36kg, closing the feed inlet, vacuumizing and filling the vacuum with nitrogen once. The stirring was switched on and the mixture was heated to an internal temperature of 55 ℃.
Removing oxygen from 174kg of purified water by thermal spraying, adding the purified water into an emulsified pan with the oxygen removed, and then adding 36kg of beta-glucan; and (4) deoxidizing the emulsifying pot again, and heating to dissolve. The dissolution temperature is 50-60 ℃, and the stirring is carried out for 20 minutes.
Adding the mixed solution of the dissolved coenzyme Q10 and the tuna oil into an emulsifying pot, starting a high-shear emulsifying machine in an anaerobic state, and emulsifying for 30-50 minutes at the emulsifying temperature of 45-60 ℃. Homogenizing the emulsified liquid under high pressure for five times, controlling the homogenizing pressure at 40Mpa, observing with an electron microscope, controlling the grain diameter of oil drops of the emulsified liquid to be 0.8 micron, adjusting the air inlet temperature of a spray dryer to be 200-240 ℃ and the air outlet temperature to be 90-130 ℃, obtaining 73.4kg of coenzyme Q10, tuna oil and beta-glucan powder, and further preparing into capsules, wherein the capsules are prepared by adopting a conventional method in the pharmaceutical field.
The capsule has the following administration effects:
liuyue Ling, female, 47 years old, and Yangzhou village under Yangzhou county, Yongchun county. The main symptoms are that after the atria are hospitalized for early time and three bottles of the medicine are taken, the symptoms disappear; after taking five bottles of the medicine, the medicine is stopped for more than one year till now, no relapse occurs, and the cure is successful. The dosage of the capsule is as follows: 1 granule/time, 1 time/day; the net content of 1 capsule is 1 g. Plum world Wei, male, 48 years old, home-holding Yongchun county Dong Ping Zhen Chin village 756. The main symptoms are that after three bottles of the medicine are taken after the ventricle is hospitalized, the symptoms disappear; after taking five bottles of the medicine, the medicine is stopped for more than one year till now, no relapse occurs, and the cure is successful. The dosage of the capsule is as follows: 1 granule/time, 1 time/day; the net content of 1 capsule is 1 g.
Example 2:
the oil melting pot is operated in an oxygen-free state in advance, namely, the oil melting pot is vacuumized, the vacuum degree reaches more than minus 0.9Mpa, a vacuum valve is closed, and nitrogen is supplemented to the normal pressure. After repeating the above operations three times, opening the charging hole, slightly opening nitrogen, adding coenzyme Q102 kg and tuna oil 40kg, closing the charging hole, vacuumizing and filling the vacuum with nitrogen once. The stirring was switched on and the mixture was heated to an internal temperature of 55 ℃.
Removing oxygen from 174kg of purified water by thermal spraying, adding the purified water into an emulsified pan with the oxygen removed, and then adding 40kg of beta-glucan; and (4) deoxidizing the emulsifying pot again, and heating to dissolve. The dissolution temperature is 50-60 ℃, and the stirring is carried out for 20 minutes.
Adding the mixed solution of the dissolved coenzyme Q10 and the tuna oil into an emulsifying pot, starting a high-shear emulsifying machine in an anaerobic state, and emulsifying for 30-50 minutes at the emulsifying temperature of 45-60 ℃. Homogenizing the emulsified liquid under high pressure at 40Mpa for five times, observing with electron microscope to obtain emulsion oil drop with particle size of 1.0 μm, adjusting air inlet temperature of spray dryer to 200-240 deg.C and air outlet temperature to 90-130 deg.C to obtain powder of coenzyme Q10, tuna oil and beta-glucan 81.6kg, and making into capsule.
Zhouwei material, male, 34 years old, home-hold Yongchun county peach town state road number 146. The main symptoms are that after the atrium is hospitalized for early time and takes two bottles of the medicine, the symptoms disappear; after four bottles of the medicine are taken, the medicine is stopped for more than one year till now, no relapse occurs, and the cure is successful. The dosage of the capsule is as follows: 1 granule/time, 1 time/day; the net content of 1 capsule is 1 g.
Chenliqing, female, 47 years old, home-hold Yongchun county grassy hill Shanzhen shop village No. 269. The main symptoms are that after the ventricle is taken with two bottles of the medicine after being hospitalized, the symptoms disappear; after four bottles of the medicine are taken, the medicine is stopped for more than one year till now, no relapse occurs, and the cure is successful. The dosage of the capsule is as follows: 1 granule/time, 1 time/day; the net content of 1 capsule is 1 g.
Example 3:
the oil melting pot is operated in an oxygen-free state in advance, namely, the oil melting pot is vacuumized, the vacuum degree reaches more than minus 0.9Mpa, a vacuum valve is closed, and nitrogen is supplemented to the normal pressure. After repeating the above operations three times, opening the charging hole, slightly opening nitrogen, adding coenzyme Q102 kg and tuna oil 44kg, closing the charging hole, vacuumizing and filling the vacuum with nitrogen once. The stirring was switched on and the mixture was heated to an internal temperature of 55 ℃.
Removing oxygen from 174kg of purified water by thermal spraying, adding the purified water into an emulsified pan with oxygen removed, and then adding 44kg of beta-glucan; and (4) deoxidizing the emulsifying pot again, and heating to dissolve. The dissolution temperature is 50-60 ℃, and the stirring is carried out for 20 minutes.
Adding the mixed solution of the dissolved coenzyme Q10 and the tuna oil into an emulsifying pot, starting a high-shear emulsifying machine in an anaerobic state, and emulsifying for 30-50 minutes at the emulsifying temperature of 45-60 ℃. Homogenizing the emulsified liquid under high pressure at 40Mpa for five times, observing with electron microscope to obtain emulsion oil droplet with particle size of 1.3 μm, adjusting air inlet temperature of spray dryer to 200-240 deg.C and air outlet temperature of 90-130 deg.C to obtain powder of 89kg coenzyme Q10, tuna oil and beta-dextran, and making into capsule.
Plum Yangjun, male, 46 years old, home-hold Yongchun county lake Yangzhou Jinfengcun No. 362. After the atria take three bottles of the medicine for medical treatment, the symptoms disappear; after taking five bottles of the medicine, the medicine is stopped for more than one year till now, no relapse occurs, and the cure is successful. The dosage of the capsule is as follows: 1 granule/time, 1 time/day; the net content of 1 capsule is 1 g. Huang nationality, man 57 years old, Shituzhen Zhen Qingqing Yuancun 841, Yongchun county. After the ventricle is hospitalized, the symptom disappears after taking three bottles of the medicine; after taking five bottles of the medicine, the medicine is stopped for more than one year till now, no relapse occurs, and the cure is successful. The dosage of the capsule is as follows: 1 granule/time, 1 time/day; the net content of 1 capsule is 1 g.
Example 4:
the beta-glucan is prepared by the following method: washing 2kg of saccharomyces cerevisiae with deionized water for three times, preparing bacterial suspension with the mass fraction of 20% by using the deionized water, and filtering by using a 100-mesh screen to remove impurities; adding 0.01kg mannanase and yeast extract enzyme (at a mass ratio of 1:1.5), performing enzymolysis at 35 deg.C and pH of 7.0 for 50min to obtain partially degraded cell membrane and yeast extract, and centrifuging to obtain cell membrane precipitate; preparing the cell membrane precipitate into 20% suspension by using 0.02mol/L phosphate buffer solution with pH 7.5, adding 0.015kg of complex enzyme (the mass ratio of the mannose to the yeast extract enzyme to the neutral protease is 1:1.5:1.5) consisting of mannase, yeast extract enzyme and neutral protease at 50 ℃ with pH 7.0, and carrying out enzymolysis for 60 min; after enzymolysis, centrifugally washing the mixture by using deionized water until supernatant is clear and transparent, and centrifugally precipitating the supernatant to obtain wet beta 1,3-1,6 glucan; spray drying: the air inlet temperature is 120 ℃, the air outlet temperature is 80 ℃, and the beta-glucan powder with uniform particles, good free flowability and purity of more than 95 percent is obtained. The mannase, the yeast extraction enzyme, the neutral protease and the saccharomyces cerevisiae used by the invention are provided by Ranen biochemistry Limited company of Quanzhou, and the enzyme activity is more than or equal to 50000 u/g.
The product form of the present invention is not limited to the embodiments, and any suitable changes or modifications of the similar ideas by anyone should be considered as not departing from the patent scope of the present invention.
Claims (4)
1. A capsule for treating atrial and ventricular premature beat, comprising a capsule and a medicinal component arranged in the capsule, wherein the medicinal component consists of the following components: coenzyme Q10, tuna oil and beta-glucan, wherein the mass ratio of the coenzyme Q10 to the tuna oil is 1: 18 to 1: 22, the mass ratio of the tuna oil to the beta-glucan is 1: 0.8 to 1: 1.2.
2. a capsule for the treatment of atrial and ventricular premature beats as in claim 1, wherein: the mass ratio of the coenzyme Q10 to the tuna oil is 1: 20, the mass ratio of the tuna oil to the beta-glucan is 1:1.
3. the preparation method of the capsule for treating the premature beat of the atria and the ventricles is characterized in that coenzyme Q10 is dissolved in tuna oil to form mixed liquid, and the mass ratio of the coenzyme Q10 to the tuna oil is 1: 18 to 1: 22, crushing the beta-glucan into particles of 0.5 to 1.5 microns by using a jet mill, uniformly distributing the beta-glucan in the mixed solution by using an emulsification homogenizer, and then preparing into capsules, wherein the mass ratio of the tuna oil to the beta-glucan is 1: 0.8 to 1: 1.2.
4. a method of making a capsule for treating atrial and ventricular premature beats as in claim 3, wherein the β -glucan is made by: washing saccharomyces cerevisiae with deionized water to prepare a bacterial suspension, and filtering to remove impurities; performing enzymolysis treatment with mannanase and yeast extraction enzyme to obtain partially degraded cell membrane and yeast extract, and centrifuging to obtain cell membrane precipitate; preparing the cell membrane precipitate into suspension by adopting phosphate buffer solution, and performing enzymolysis treatment by using a complex enzyme consisting of mannanase, yeast extract enzyme and neutral protease; after enzymolysis, centrifugally washing the mixture by using deionized water until supernatant is clear and transparent, and centrifugally precipitating the supernatant to obtain wet beta 1,3-1,6 glucan; drying to obtain beta-glucan powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111106550.8A CN113633664A (en) | 2021-09-22 | 2021-09-22 | Capsule for treating atrial and ventricular premature beat and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111106550.8A CN113633664A (en) | 2021-09-22 | 2021-09-22 | Capsule for treating atrial and ventricular premature beat and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113633664A true CN113633664A (en) | 2021-11-12 |
Family
ID=78426300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111106550.8A Pending CN113633664A (en) | 2021-09-22 | 2021-09-22 | Capsule for treating atrial and ventricular premature beat and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113633664A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796259A (en) * | 2022-02-17 | 2022-07-29 | 泉州雷恩生化有限公司 | Medicine for inhibiting pulmonary nodule and inflammation and its preparing method |
| CN117338748A (en) * | 2023-11-17 | 2024-01-05 | 泉州雷恩生化有限公司 | Capsule for treating atrial and ventricular premature beat and its preparing process |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103044572A (en) * | 2013-01-06 | 2013-04-17 | 中国农业科学院农产品加工研究所 | Preparation method of yeast beta-D-glucan |
| CA2895069A1 (en) * | 2012-12-27 | 2014-07-03 | Leendert Taal | Medical formulation for treating hypercholesterolemia |
| CN105079009A (en) * | 2015-08-25 | 2015-11-25 | 厦门金达威集团股份有限公司 | Composition for preventing and /or treating cardiovascular and cerebrovascular diseases |
-
2021
- 2021-09-22 CN CN202111106550.8A patent/CN113633664A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2895069A1 (en) * | 2012-12-27 | 2014-07-03 | Leendert Taal | Medical formulation for treating hypercholesterolemia |
| CN103044572A (en) * | 2013-01-06 | 2013-04-17 | 中国农业科学院农产品加工研究所 | Preparation method of yeast beta-D-glucan |
| CN105079009A (en) * | 2015-08-25 | 2015-11-25 | 厦门金达威集团股份有限公司 | Composition for preventing and /or treating cardiovascular and cerebrovascular diseases |
Non-Patent Citations (4)
| Title |
|---|
| SIGAL EILAT-ADAR等: ""Nutritional Recommendations for Cardiovascular Disease Prevention"", 《NUTRIENTS》, vol. 5, 17 September 2013 (2013-09-17), pages 3646 - 3683 * |
| 吴祖芳 等: ""辅酶Q10的功能研究进展"", 《宁波大学学报理工版》 * |
| 吴祖芳 等: ""辅酶Q10的功能研究进展"", 《宁波大学学报理工版》, vol. 14, no. 2, 30 June 2001 (2001-06-30), pages 85 - 88 * |
| 姜锡瑞 等: "《生物发酵产业技术》", vol. 1, 中国轻工业出版社, pages: 253 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796259A (en) * | 2022-02-17 | 2022-07-29 | 泉州雷恩生化有限公司 | Medicine for inhibiting pulmonary nodule and inflammation and its preparing method |
| CN114796259B (en) * | 2022-02-17 | 2024-06-07 | 泉州雷恩生化有限公司 | Medicine for inhibiting pulmonary nodule and inflammation and its prepn |
| CN117338748A (en) * | 2023-11-17 | 2024-01-05 | 泉州雷恩生化有限公司 | Capsule for treating atrial and ventricular premature beat and its preparing process |
| CN117338748B (en) * | 2023-11-17 | 2024-04-05 | 泉州雷恩生化有限公司 | Capsule for treating atrial and ventricular premature beat and its preparing process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113633664A (en) | Capsule for treating atrial and ventricular premature beat and its preparing process | |
| CN105837700A (en) | A comprehensive extraction, utilization and production method for glossy ganoderma sporocarps and spores | |
| CN101347216B (en) | Method for preparing nutritional concentrated solution of red date | |
| CN104840501B (en) | A kind of preparation method of chrysanthemum total flavone | |
| CN102898539A (en) | Method for subcritical water extraction of ganoderma lucidum polysaccharides | |
| CN103251054A (en) | Anti-fatigue health protection food composition and preparation method thereof | |
| CN107573317A (en) | A kind of extracting method of blueberry anthocyanin | |
| CN106749731A (en) | A kind of preparation method and application of small molecule notoginseng polysaccharide extract | |
| CN105418785B (en) | A kind of production method of Radix Et Caulis Acanthopanacis Senticosi polysaccharide and its application | |
| CN107286264A (en) | The deep working method of Chinese date nutrient material separation | |
| CN105410279A (en) | Composite tea composed of extracts of siraitia grosvenorii and radix isatidis and preparation method thereof | |
| CN104758331A (en) | Chinese medicine composition capable of enhancing immunity and preparation method thereof | |
| CN110664860B (en) | Composition for enhancing immunity and preparation method thereof | |
| CN102492667A (en) | Enzyme preparation, and application of same in extraction of phellodendron berberine and method thereof | |
| CN101333241B (en) | Process for extracting dioscin, preparation thereof and use | |
| CN105111323B (en) | A kind of method for extraction and purification of the black nightshade refined polysaccharide with antitumor activity | |
| CN1067244C (en) | Notoginsenoside powder injection | |
| CN105433260A (en) | Health-care food for reducing blood fat and preparation process thereof | |
| CN108969580B (en) | Preparation method and application of blue cloth total tannin | |
| CN107501432A (en) | A kind of gold thread grass polysaccharide extract and preparation method thereof and purposes | |
| CN104758698A (en) | Traditional Chinese medicine composition for treating hepatic fibrosis | |
| CN101647858B (en) | Preparation method of water-soluble extract of red sage root | |
| CN104547026B (en) | Preparation method and application of salvia miltiorrhiza leave pseudo-ginseng extract | |
| CN106901325A (en) | A kind of preparation and application of ganoderma lucidum full agonist | |
| CN102429942A (en) | Freeze-drying method of pseudo-ginseng total saponin freeze-dried injection powder with filling amount more than 500 mg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211112 |